49842-07-1

• 常用中文名：硫酸妥布霉素
• 常用英文名：Dicon
• CAS号：49842-07-1
• 分子式：C₁₈H₃₇N₅O_9.5/₂H₂O₄S
• 分子量：565.593
• 相关类别： 原料药 抗生素类药物 氨基糖苷类药
• 发布时间：2018-05-18 08:00:00
• 更新时间：2024-01-13 19:09:57
• Tobramycin sulfate (Nebramycin Factor 6 sulfate) 是一种胃肠外给药的广谱氨基糖苷类抗生素,已广泛用于治疗由于敏感生物引起的中度至重度细菌感染。

名称

• 中文名: 硫酸妥布霉素
• 英文名: (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol,sulfuric acid
• 中文别名: O-3-氨基-3-脱氧-alpha-O-葡吡喃糖基-(1→6)-O-[2,6-二氨基-2,3,6-三脱氧-alpha-D-核-己吡喃糖基-(1→4)]-2-脱氧-D-链霉胺硫酸盐; 硫酸托布霉素; 妥布霉素硫酸盐
• 英文别名: Tobra; 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine; 1-(3,4-dimethoxy-phenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine; (2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminométhyl)-5-hydroxytétrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxyméthyl)tétrahydro-2H-pyran; (2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol sulfate (salt); 1-Epitobramycin sulfate; Tobra Gobens; Tomycin; EINECS 256-499-2; 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-; 5-aethyl-1-(3,4-dimethoxyphenyl)-7,8-dimethoxy-4-methyl-5H-benzodiazepin; (1S,2S,3R,4S,6R)-4,6-Diamino-3-[(2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-α-D-glucopyranoside sulfate (salt); Dicon; Egyt 341; Obracine; EINECS 244-922-3; (1S,2S,3R,4S,6R)-4,6-Diamino-3-[(2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-α-D-glucopyranoside sulfate (1:1); Dartobcin; Tofisopamum [INN-Latin]; Nebicina; Tobracin; Tofisopam [INN:DCF:JAN]; Emandaxin; Nebcine; UNII:UZC80HAU42; Gernebcin; Obracin; Tobraneg; Tobramycin sulphate; 7,8-dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine; -3,5-diol sulfate (salt); -3,5-diolsulfat(salt); (2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminométhyl)-5-hydroxytétrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxyméthyl)tétrahydro-2H-pyran-3,5-diol sulfate (salt); Tenemicin; Tobrasix; Grandaxin; 1-[3,4-bis(methyloxy)phenyl]-5-ethyl-4-methyl-7,8-bis(methyloxy)-5H-2,3-benzodiazepine; Tofisopam; Nebcin; 1-(3,4-dimethoxyphenyl)-7,8-dimethoxy-5-ethyl-4-methyl-5H-2,3-benzodiazepine; α-D-Glucopyranoside, (1S,2S,3R,4S,6R)-4,6-diamino-3-[(2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-, sulfate (1:1) (salt); 7,8-Dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine,EGYT 341,Seriel; Trazil; tofizopam; Tobryne; (2S,3R,4S,5S,6R)-4-Amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran; Seriel; (2S,3R,4S,5S,6R)-4-Amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diolsulfat(salt)

物化性质

• 密度: 1.52g/cm3
• 沸点: 775.4ºC at 760mmHg
• 分子式: C₁₈H₃₇N₅O_9.5/₂H₂O₄S
• 分子量: 565.593
• 闪点: 422.8ºC
• 精确质量: 565.226501
• PSA: 351.15000
• 外观性状: 粉末
• 储存条件: 2-8°C
• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:12

  3.氢键受体数量:18

  4.可旋转化学键数量:6

  5.互变异构体数量:无

  6.拓扑分子极性表面积351

  7.重原子数量:37

  8.表面电荷:0

  9.复杂度:691

  10.同位素原子数量:0

  11.确定原子立构中心数量:14

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:2

生物活性

• 描述: Tobramycin sulfate (Nebramycin Factor 6 sulfate) 是一种胃肠外给药的广谱氨基糖苷类抗生素,已广泛用于治疗由于敏感生物引起的中度至重度细菌感染。
• 相关类别:
  研究领域 >> 感染
  信号通路 >> 抗感染 >> 细菌
• 参考文献:

  [1]. Tobramycin.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : WK2110000 CHEMICAL NAME : Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6 -diamino-2,3,6-trideo xy- alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-, D-, sulfate (salt) CAS REGISTRY NUMBER : 49842-07-1 LAST UPDATED : 199606 DATA ITEMS CITED : 12 MOLECULAR FORMULA : C18-H37-N5-O9.xH2-O4-S MOLECULAR WEIGHT : 1154.16 WISWESSER LINE NOTATION : T6OTJ B1Q CQ DZ EQ FO- BL6TJ AZ CQ EZ DO- BT6OTJ CZ EQ F1Z &..H2.S-O4 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Human - woman DOSE/DURATION : 15 mg/kg/5D-I TOXIC EFFECTS : Behavioral - wakefulness Behavioral - hallucinations, distorted perceptions REFERENCE : JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1883- Volume(issue)/page/year: 247,1319,1982 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1680 mg/kg TOXIC EFFECTS : Autonomic Nervous System - other (direct) parasympathomimetic Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea REFERENCE : ANTBAL Antibiotiki. (Moscow, USSR) V.1-29, 1956-84. For publisher information, see AMBIEH. Volume(issue)/page/year: 24,60,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 126 mg/kg TOXIC EFFECTS : Autonomic Nervous System - other (direct) parasympathomimetic Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea REFERENCE : ANTBAL Antibiotiki. (Moscow, USSR) V.1-29, 1956-84. For publisher information, see AMBIEH. Volume(issue)/page/year: 24,60,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >10500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : ANTBAL Antibiotiki. (Moscow, USSR) V.1-29, 1956-84. For publisher information, see AMBIEH. Volume(issue)/page/year: 24,60,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 262 mg/kg TOXIC EFFECTS : Autonomic Nervous System - other (direct) parasympathomimetic Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea REFERENCE : ANTBAL Antibiotiki. (Moscow, USSR) V.1-29, 1956-84. For publisher information, see AMBIEH. Volume(issue)/page/year: 24,60,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 560 mg/kg TOXIC EFFECTS : Autonomic Nervous System - other (direct) parasympathomimetic Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea REFERENCE : ANTBAL Antibiotiki. (Moscow, USSR) V.1-29, 1956-84. For publisher information, see AMBIEH. Volume(issue)/page/year: 24,60,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 77 mg/kg TOXIC EFFECTS : Autonomic Nervous System - other (direct) parasympathomimetic Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea REFERENCE : ANTBAL Antibiotiki. (Moscow, USSR) V.1-29, 1956-84. For publisher information, see AMBIEH. Volume(issue)/page/year: 24,60,1979 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1600 mg/kg/8D-I TOXIC EFFECTS : Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Endocrine - changes in adrenal weight Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases REFERENCE : ANTBAL Antibiotiki. (Moscow, USSR) V.1-29, 1956-84. For publisher information, see AMBIEH. Volume(issue)/page/year: 24,60,1979 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Mammal - cat DOSE/DURATION : 8400 mg/kg/30W-I TOXIC EFFECTS : Sense Organs and Special Senses (Ear) - changes in cochlear structure or function Behavioral - altered sleep time (including change in righting reflex) Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) REFERENCE : TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 77,479,1985 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Rodent - guinea pig DOSE/DURATION : 1400 mg/kg/14D-I TOXIC EFFECTS : Sense Organs and Special Senses (Ear) - changes in cochlear structure or function REFERENCE : LARYA8 Laryngoscope. (Laryngoscope Co., 9216 Clayton Rd., Suite 18, St. Louis, MO 63124) V.1- 1896- Volume(issue)/page/year: 86,259,1976 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Rodent - guinea pig DOSE/DURATION : 1400 mg/kg/7D-I TOXIC EFFECTS : Sense Organs and Special Senses (Ear) - changes in cochlear structure or function REFERENCE : LARYA8 Laryngoscope. (Laryngoscope Co., 9216 Clayton Rd., Suite 18, St. Louis, MO 63124) V.1- 1896- Volume(issue)/page/year: 86,259,1976 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4326 No. of Facilities: 305 (estimated) No. of Industries: 1 No. of Occupations: 7 No. of Employees: 21896 (estimated) No. of Female Employees: 17672 (estimated)

安全

• 危害码 (欧洲): T: Toxic;
• 风险声明 (欧洲): R61
• 安全声明 (欧洲): 53-22-36/37/39-45
• WGK德国: 3